None listed
Conditions
Brief summary
As a result of climate change, the incidence of heat illnesses has increased in the general population, with fatalities evident in those exposed to exertional-heat stress (e.g., mining, agriculture, military, and sport). The pathophysiology of heat illnesses (i.e., high body temperature), stems from metabolic heat production, ambient conditions, gut and immune responses. Thus, the aim of the current study is to assess if the consumption of a dairy product may provide support in adapting the human body to cope with the increased daily ambient temperature associated with the present global warming crisis. It is hypothesized that a one-week increased consumption of dairy beverages, rich in fermentable lactose and ß-GOS, and protein availability, will suppress gastrointestinal and immune perturbations linked with the pathophysiological pathway of heatstroke.
Interventions
Arm 1 (treatment trial): twice daily (once in the AM, once in the PM) oral consumption for 7 days (in the participants location of choice) of 400 mL skim milk (cows milk) with beta-galactooligosaccharides and natural flavouring added. Adherence of consumption will be monitored via a consumption compliance data sheet. Participants will then complete 2 hours of running exercise at 60% of their pre-determined VO2max in 35 degrees celsius after completing the 7-day consumption of the skim milk bever
Arm 1 (treatment trial): twice daily (once in the AM, once in the PM) oral consumption for 7 days (in the participants location of choice) of 400 mL skim milk (cows milk) with beta-galactooligosaccharides and natural flavouring added. Adherence of consumption will be monitored via a consumption compliance data sheet. Participants will then complete 2 hours of running exercise at 60% of their pre-determined VO2max in 35 degrees celsius after completing the 7-day consumption of the skim milk beverage. There will be a minimum of 7 days of wash out between treatments.
Sponsors
Ricardo Costa - Monash University
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
• 18 years or more, but no more than 49 years of age. • Endurance trained individual. • Minimum capacity of 45 mL/kg/min VO2max.
Exclusion criteria
• No health conditions that may affect participation (e.g., diabetes, cardiovascular disease, hypertension, liver or thyroid dysfunction, and/or a recent major surgery and/or implanted cardiac defibrillator). • Not a smoker or vaper. • Able to adhere to the study protocol and consume every study food. • Available to attend three testing sessions at the BASE Facility, 264 Ferntree Gully Road, Notting Hill. • Not pregnant, planning on becoming pregnant, and/or breastfeeding. • Not an individual presenting a clinical diagnosis of gastrointestinal disease or disorders, or an individual presenting any other forms of illness or infection due to confounding effects on gastrointestinal markers/outcomes. • No history of gastrointestinal surgery, and/or other self-reported gastrointestinal issues, consume potential modifiers of gastrointestinal integrity (such as prebiotics, probiotics, and/or antibiotics), adhering to gastrointestinal-focused dietary regimes (such as low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) or fibre-modified diets) within 3 months prior to study. • No consumption of non-steroidal anti-inflammatory medications and/or stool-altering medications (e.g., laxatives and anti-diarrhoea) within 1 month prior to the experimental protocol. • Not an individual presenting soft tissue injury 1 month prior to participation due to risk of recurrence of injury. • Not an individual with lactose intolerance.
Outcome results
None listed